Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheila DeWitt

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
ACS Medicinal Chemistry Letters|October 16, 2020
Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting RacematesSheila DeWitt, Anthony W Czarnik, Vincent Jacques
Journal of Inherited Metabolic Disease|May 5, 2022
Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophyPierre-Axel Monternier, Jaspreet Singh, Parveen Parasar, et al.
Hepatology Communications|August 25, 2021
Deuterium-Stabilized (<i>R</i>)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ ActivityVincent Jacques, Sébastien Bolze, Sophie Hallakou-Bozec, et al.
Journal of Hepatology|February 22, 2023
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Stephen A Harrison, Carole Thang, Sébastien Bolze, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|October 16, 2020
Deuterium-Enabled Chiral Switching (DECS) Yields Chirally Pure Drugs from Chemically Interconverting RacematesSheila DeWitt, Anthony W Czarnik, Vincent Jacques
Journal of Inherited Metabolic Disease|May 5, 2022
Therapeutic potential of deuterium-stabilized (R)-pioglitazone-PXL065-for X-linked adrenoleukodystrophyPierre-Axel Monternier, Jaspreet Singh, Parveen Parasar, et al.
Hepatology Communications|August 25, 2021
Deuterium-Stabilized (<i>R</i>)-Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ ActivityVincent Jacques, Sébastien Bolze, Sophie Hallakou-Bozec, et al.
Journal of Hepatology|February 22, 2023
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Stephen A Harrison, Carole Thang, Sébastien Bolze, et al.
Pageof 1